| Field | Specification |
|---|---|
| Alternative names | IMMU-132 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Purity | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Sacituzumab govitecan, also known as IMMU-132, is an antibody-drug conjugate (ADC) that targets Trop-2 to deliver SN-38. The antibody component is Sacituzumab, and CL2A-SN-38 serves as the drug-linker conjugate used for ADC construction. Anticancer activity has been reported for the compound[1]. It is supplied as a white to off-white solid at 98.02% purity, with an average molecular weight of 157364 g/mol.
Physical & Chemical Properties
| CAS Number | 1491917-83-9 |
|---|---|
| Molecular Weight | 157364 g/mol (average) |
| Purity | 98.02% |
| Appearance | Solid |
| Color | White to off-white |
| Signaling Pathway | Antibody-Drug Conjugate/ADC Related; Immunology/Inflammation |
| Solubility | In Vitro: H2O: 25 mg/mL (Requires sonication) |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Shipping with dry ice. |
| Preparation Instructions | The product can be reconstituted/diluted with sterile PBS or saline. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| H2O | 25 mg/mL | requires sonication |
Data provided by the manufacturer.
In Vitro
Sacituzumab govitecan (10 μM; 48 h) raises the early pro-apoptotic signaling markers (cleaved caspase3/7, cleaved PARP, p53 and p21) and causes PARP cleavage and apoptosis[3].
Western Blot Analysis[3]
| Cell Line | NCI-N87, BxPC-3 |
|---|---|
| Concentration | 10 μM |
| Incubation Time | 48 h |
| Result | Increased cleaved caspase 3/7 and cleaved PARP. |
In Vivo
In mice bearing human gastric cancer xenografts, Sacituzumab govitecan (IMMU-132) (17.5 mg/kg; twice weekly for 4 weeks) yields significant antitumor effects[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
TROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer. Nature 2026 Aug;656(8129):1023-1033. PMID: 42386981
A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. Cell Rep Med 2026 Apr 21;7(4):102688. PMID: 41856115
In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. J Control Release 2024 Mar:367:779-790. PMID: 38346501
MMP1-induced NF-κB activation promotes epithelial-mesenchymal transition and sacituzumab govitecan resistance in hormone receptor-positive breast cancer. Cell Death Dis 2025 Apr 26;16(1):346. PMID: 40287412
A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy. Int J Biol Macromol 2025 Apr 3;309(Pt 1):142843. PMID: 40187454
Preclinical Evaluation of a Trop2-Targeted Peptide Probe for PET Imaging of Triple-Negative Breast Cancer. Anal Chem 2025 Oct 28;97(42):23598-23608. PMID: 41105928
Novel Aptamer-Drug Conjugate for Targeted Therapy in Triple-Negative Breast Cancer. J Med Chem 2025 Jul 20. PMID: 40685636
TROP-2 Promotes Cell Proliferation via the AKT-Mediated PKC α Pathway and Is a Novel Target for Antibody-Drug Conjugates in Penile Carcinoma. Oncol Res 2025 Nov 27;33(12):3973-3989. PMID: 41425706
TROP2 expression and therapeutic targeting in uterine carcinosarcoma. Gynecol Oncol 2025 May 8:197:129-138. PMID: 40344963
Design and synthesis of novel site-specific antibody-drug conjugates that target TROP2. Bioorg Med Chem 2024 Aug 1:110:117828. PMID: 38981219
